Palatin Technologies

Palatin Technologies is a biopharmaceutical company focused on developing innovative therapeutics for patients with inflammatory and autoimmune conditions. The company's successful FDA approval of Vyleesi®, a treatment for women with hypoactive sexual desire disorder (HSDD), demonstrates its expertise in the development of melanocortin-based therapeutics. Palatin is now directing its efforts towards leveraging the melanocortin system to address harmful inflammation in conditions affecting the eye, gastrointestinal system, and kidney. The company's leading ocular product, PL9643, designed to treat dry eye disease, is poised to enter Phase 3 clinical trials in the second half of 2021. Additionally, Palatin is advancing therapeutics for ophthalmic indications such as non-infectious uveitis, retinopathies, and corneal diseases. With plans for proof of concept clinical studies in ulcerative colitis and kidney disease, Palatin aims to demonstrate the broad utility of melanocortin system-modulating therapeutics. Vyleesi® stands out as the first and only on-demand, FDA-approved treatment for premenopausal women with HSDD, a condition affecting 1 in 10 pre-menopausal women. Palatin's commitment to positively impacting patient lives and creating value for shareholders is exemplified through its therapeutic programs and milestones in the biotechnology and healthcare industries. For further information on Palatin Technologies and its programs, visit www.palatin.com.